CHERRICE CLAY-AUSTIN: Open Payments
NPI 1821340597 · MACON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$829 in 37 payments from 12 companies in 2025. Trend: 2023 $294 · 2024 $934 · 2025 $829
Food & beverage: $829
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $276 |
| AstraZeneca Pharmaceuticals LP | 5 | $188 |
| Novo Nordisk Inc | 5 | $99 |
| Merck Sharp & Dohme LLC | 4 | $61 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Novartis Pharmaceuticals Corporation | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| PFIZER INC. | 1 | $24 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $22 |
| Exact Sciences Corporation | 1 | $15 |
Products named: QULIPTA, AIRSUPRA, Ozempic, UBRELVY, VERQUVO, TRELEGY ELLIPTA, FARXIGA, VRAYLAR.
Industry payments across GA — which companies pay providers there.
